Payment overview · 2025
General Payments
$2,070.27
106 reported records · 24 companies
Healthcare provider profile · identity verified
Alan Michael Hicks, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MORGANTON, NC · NPI 1720503972
Verified facts
What the public records show
CMS Open Payments records show Alan Michael Hicks, NP-C received $2,070.27 in general payments during 2025 across 106 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $492.45 | 23.8% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $237.76 | 11.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $172.39 | 8.3% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $147.41 | 7.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.30 | 6.9% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $142.28 | 6.9% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $113.39 | 5.5% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $77.57 | 3.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.83 | 3.4% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.93 | 2.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.25 | 2.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $54.65 | 2.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.28 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.94 | 2.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.18 | 1.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.98 | 1.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.96 | 1.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.61 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.28 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.14 | 0.9% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $16.60 | 0.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $15.46 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.88 | 0.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.75 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,958.78 | 105 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $281.74 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $188.56 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $154.85 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $147.41 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $135.79 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $113.39 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $99.22 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.79 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.65 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $77.57 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.94 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.94 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.32 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.83 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.36 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $60.93 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 57 |
| Omeprazole | Omeprazole | 265 | 51 |
| Gabapentin | Gabapentin | 247 | 53 |
| Alprazolam | Alprazolam | 236 | 26 |
| Lisinopril | Lisinopril | 215 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 211 | 30 |
| Meloxicam | Meloxicam | 199 | 34 |
| Metformin Hcl Er | Metformin Hcl | 199 | 38 |
| Furosemide | Furosemide | 192 | 42 |
| Montelukast Sodium | Montelukast Sodium | 169 | 33 |
| Tramadol Hcl | Tramadol Hcl | 163 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 66 |
| Prednisone | Prednisone | 152 | 87 |
| Trazodone Hcl | Trazodone Hcl | 152 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 25 |
| Clonazepam | Clonazepam | 122 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 26 |
| Lorazepam | Lorazepam | 112 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 106 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 106 | 22 |
| Losartan Potassium | Losartan Potassium | 103 | 26 |
| Pregabalin | Pregabalin | 102 | 18 |
| Ozempic | Semaglutide | 97 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 17 |
| Potassium Chloride | Potassium Chloride | 90 | 21 |
| Celecoxib | Celecoxib | 88 | 18 |
| Bupropion Xl | Bupropion Hcl | 85 | 14 |
| Aripiprazole | Aripiprazole | 84 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 14 |
| Ondansetron Odt | Ondansetron | 76 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 11 |
| Diazepam | Diazepam | 71 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 46 |
| Simvastatin | Simvastatin | 70 | 14 |
| Buspirone Hcl | Buspirone Hcl | 68 | 14 |
| Mounjaro | Tirzepatide | 68 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 19 |
| Carvedilol | Carvedilol | 65 | 15 |
| Spironolactone | Spironolactone | 64 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 61 | 12 |
| Atenolol | Atenolol | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 39 |
| Eliquis | Apixaban | 52 | suppressed |
| Linzess | Linaclotide | 52 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 19 |
| Risperidone | Risperidone | 51 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 11 |
| Allopurinol | Allopurinol | 48 | 11 |
| Topiramate | Topiramate | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 14 |
| Eszopiclone | Eszopiclone | 44 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Nystatin | Nystatin | 41 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 41 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 25 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 11 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 25 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Olanzapine Odt | Olanzapine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,070.27 · 106 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, Dyanavel XR, ETERNA, FANAPT, FARXIGA, IBSRELA, INVEGA SUSTENNA, JARDIANCE, Kerendia, LYBALVI, MOUNJARO, NURTEC ODT, NUZYRA, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error